Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nephropathy Clear all
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Jun 10, 2026, 6:21 PM EDT
Completed No phase listed Observational

VIDAS® NEPHROCLEAR Diagnostic Accuracy Study

NCT06036758
View directory record Official record
Conditions
Acute Kidney Injury, Stage 2 Acute Kidney Injury, Stage 3 Acute Kidney Injury
Interventions
VIDAS® NEPHROCLEAR™ CCL14 Test
Diagnostic Test
Lead sponsor
BioMérieux
Industry
Eligibility
21 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jun 10, 2026, 6:21 PM EDT
Recruiting Phase 2 Interventional

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 20 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 10, 2026, 6:21 PM EDT
Recruiting Not applicable Interventional

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

NCT05655325
View directory record Official record
Conditions
Mild Cognitive Impairment, Chronic Kidney Diseases
Interventions
Home-based walking exercise, Attention control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT00098618
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Jun 10, 2026, 6:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

NCT01087333
View directory record Official record
Conditions
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 6:21 PM EDT
Terminated Phase 4 Interventional Results available

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

NCT00209417
View directory record Official record
Conditions
Renal Insufficiency, Diabetes Mellitus
Interventions
Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Jun 10, 2026, 6:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

NCT00900276
View directory record Official record
Conditions
Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
immunologic technique, laboratory biomarker analysis, mass spectrometry
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 10, 2026, 6:21 PM EDT
Completed No phase listed Observational

Nova Max Creatinine and eGFR Meter System

NCT05118074
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Kidney Injury
Interventions
Creatinine, eGFR
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Medley, Florida • Miami Gardens, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jun 10, 2026, 6:21 PM EDT
Recruiting Phase 2 Interventional

Improving Preterm Kidney Outcomes With Caffeine

NCT07262060
View directory record Official record
Conditions
Kidney Injury, Pre-Term
Interventions
Caffeine citrate, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Hours to 96 Hours
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Seattle Cardiorenal Remote Ischemic Preconditioning Trial

NCT01260259
View directory record Official record
Conditions
Congenital Heart Disease, Cardiopulmonary Bypass, Myocardial Injury, Acute Kidney Injury, Acute Lung Injury
Interventions
RIPC, Control
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jun 10, 2026, 6:21 PM EDT
Not listed Phase 1 Interventional

Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution

NCT02663596
View directory record Official record
Conditions
Pediatric Continuous Renal Replacement Therapy, Dialysis, Renal Failure
Interventions
Vancomycin
Drug
Lead sponsor
Drexel University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 10, 2026, 6:21 PM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 10, 2026, 6:21 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

NCT03024996
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Scottsdale, Arizona • Duarte, California • Lancaster, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Jun 10, 2026, 6:21 PM EDT
Not listed Phase 1 Interventional

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

NCT01165762
View directory record Official record
Conditions
ESRD
Interventions
Immune Tolerance
Drug
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jun 10, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

NCT00523640
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
combination of gemcitabine, capecitabine, and bevacizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jun 10, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

NCT05624723
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jun 10, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Safety Study of MGA271 in Refractory Cancer

NCT01391143
View directory record Official record
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jun 10, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Comparison of Standard Versus Low Bicarbonate Hemodialysis

NCT01777178
View directory record Official record
Conditions
Chronic Kidney Disease, Metabolic Acidosis
Interventions
Low bicarbonate dialysis
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jun 10, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

NCT02052310
View directory record Official record
Conditions
Anemia in Incident Dialysis Patients
Interventions
Roxadustat, Epoetin Alfa
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Chula Vista, California • La Mesa, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Jun 10, 2026, 6:21 PM EDT
Terminated No phase listed Observational

Immunoparalysis in Acute Kidney Injury After Cardiac Surgery

NCT03922958
View directory record Official record
Conditions
Acute Kidney Injury, Immune Deficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jun 10, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

NCT04486625
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Aztreonam-Avibactam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jun 10, 2026, 6:21 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

NCT07315360
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 10, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

NCT04846920
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 6:21 PM EDT